These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25692853)

  • 1. Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the Future.
    Arbiser JL
    JAMA Dermatol; 2015 Jul; 151(7):703-4. PubMed ID: 25692853
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
    Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
    JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
    Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
    Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
    Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors.
    Lam C; Bouffet E; Tabori U; Mabbott D; Taylor M; Bartels U
    Pediatr Blood Cancer; 2010 Mar; 54(3):476-9. PubMed ID: 19856393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.
    Muzic JG; Kindle SA; Tollefson MM
    JAMA Dermatol; 2014 Sep; 150(9):1024-5. PubMed ID: 24919623
    [No Abstract]   [Full Text] [Related]  

  • 7. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
    Leducq S; Giraudeau B; Tavernier E; Maruani A
    J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus for Retinal Astrocytic Hamartoma Associated with Tuberous Sclerosis Complex.
    Zhang ZQ; Shen C; Long Q; Yang ZK; Dai RP; Wang J; Zhang W; Pan Q; Zhu Z; Xu KF
    Ophthalmology; 2015 Sep; 122(9):1947-9. PubMed ID: 25912145
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
    Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M
    Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
    Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
    Arch Dermatol; 2012 Jan; 148(1):138-9. PubMed ID: 22250258
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis.
    Cabrera López C; Martí T; Catalá V; Torres F; Mateu S; Ballarín Castán J; Torra Balcells R
    Nefrologia; 2011; 31(3):292-8. PubMed ID: 21629335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86.
    Canpolat M; Per H; Gumus H; Yikilmaz A; Unal E; Patiroglu T; Cinar L; Kurtsoy A; Kumandas S
    Childs Nerv Syst; 2014 Feb; 30(2):227-40. PubMed ID: 23743820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
    Nathan N; Wang JA; Li S; Cowen EW; Haughey M; Moss J; Darling TN
    J Am Acad Dermatol; 2015 Nov; 73(5):802-8. PubMed ID: 26365597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
    Jozwiak J; Jozwiak S; Oldak M
    Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrous Cephalic Plaque in Tuberous Sclerosis Complex: Treatment With 0.2% Rapamycin.
    Giacaman A; Martín-Santiago A
    Actas Dermosifiliogr (Engl Ed); 2019 Jun; 110(5):e13. PubMed ID: 30846165
    [No Abstract]   [Full Text] [Related]  

  • 18. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermoscopy of hypopigmented macules unveiling genetic diagnosis of tuberous sclerosis complex type 2 in an infant presenting with sacral chordoma.
    Sharma A; Aggarwal B; Kakkar A; Pandey NN; Taneja N
    Pediatr Dermatol; 2024; 41(4):736-738. PubMed ID: 38500310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
    Cheng S; Hawkins C; Taylor MD; Bartels U
    Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.